title: Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.
abstract: With the availability of the nonavalent human papillomavirus (HPV) vaccine, vaccinees, parents and healthcare providers need guidance on how to complete an immunization course started with the bi- or quadrivalent vaccine and whether to revaccinate individuals who have completed a full immunization course with the bi- or quadrivalent vaccine. To answer these questions three parameters should be considered: age at the start of vaccination (9 to 14 years of age versus 15 years and older, the cut-off for 2 or 3 doses schedule), the number of doses already received and the time interval between doses. Based on a number of scenarios, we propose that the 9-valent vaccine can be used to complete an incomplete vaccination regimen or might be added to a previous completed schedule to extend protection.
authors.affiliation: Centre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium. Electronic address: pierre.vandamme@uantwerp.be.
authors.forename: Pierre
authors.initials: P
authors.lastname: Van Damme
authors.affiliation: Department of Health Sciences, University of Florence, Florence, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Bonanni
authors.affiliation: Cancer Research Epidemiology Program, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain.
authors.forename: F Xavier
authors.initials: FX
authors.lastname: Bosch
authors.affiliation: Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
authors.forename: Elmar
authors.initials: E
authors.lastname: Joura
authors.affiliation: Department of Gynaecology, Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital and the University of Copenhagen, Copenhagen, Denmark.
authors.forename: Susanne Krüger
authors.initials: SK
authors.lastname: Kjaer
authors.affiliation: Department of Pathology, Free University Medical Center, Amsterdam, The Netherlands.
authors.forename: Chris J L M
authors.initials: CJ
authors.lastname: Meijer
authors.affiliation: Department of Gynaecology and Obstetrics, Klinikum Wolfsburg, Wolfsburg, Germany.
authors.forename: Karl-Ulrich
authors.initials: KU
authors.lastname: Petry
authors.affiliation: Sanofi Pasteur MSD, Department of Medical Affairs, Lyon, France.
authors.forename: Benoit
authors.initials: B
authors.lastname: Soubeyrand
authors.affiliation: P95, Epidemiology and Pharmacovigilance Consulting and Services, Leuven, Belgium.
authors.forename: Thomas
authors.initials: T
authors.lastname: Verstraeten
authors.affiliation: Department of Pathology, Cambridge University, Cambridge, UK.
authors.forename: Margaret
authors.initials: M
authors.lastname: Stanley
mesh_terms: D000293:Adolescent; D002648:Child; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D030361:Papillomavirus Infections / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines
keywords: Cervical cancer; Human papillomavirus; Revaccination